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Effect of inhaled substance P and neurokinin A on the
airways of normal and asthmatic subjects
G JOOS, R PAUWELS, M VAN DER STRAETEN
From the Department ofRespiratory Diseases, University Hospital, Ghent, Belgium
ABSTRACT The neuropeptides substance P and neurokinin A are present in sensory airway nerves.
Their effect on airway calibre was compared in six healthy non-smoking subjects and six asthmatic
subjects. On separate days increasing concentrations (from 10-9 to 10'6 mol/ml) of each neu-
ropeptide were administered by nebuliser and the airway response measured as change in specific
airway conductance (sGaw). Substance P and neurokinin A caused no change in sGaw in the
healthy subjects. Inhalation of substance P up to the highest concentration of 106 mol/ml caused
no change in sGaw in the asthmatic subjects. Neurokinin A, however, caused
bronchoconstriction with a mean fall in sGaw of 48% (SEM 12%) after 5 x 10- mol/ml. The
onset of bronchoconstriction was rapid, but sGaw had returned to baseline values within one hour
in all but one patient.
Several neuropeptides have been detected in the air-
way by immunological techniques.' These include
substance P and neurokinin A, two members of the
tachykinin peptide family. These structurally related
peptides are potent smooth muscle constrictors and
blood vessel dilators.2
Substance P has been localised within sensory air-
way nerves of animals and man: nerve fibres with sub-
stance P like immunoreactivity have been seen in the
airway mucosa; around blood vessels, submucosal
glands, and tracheobronchial ganglion cells; and
within airway smooth muscle.34
Neurokinin A is a recently discovered mammalian
tachykinin, whose structure is contained, with sub-
stance P, in one of the two mammalian tachykinin
precursors, ,B preprotachykinin.5 Neurokinin A co-
exists with substance P within peripheral sensory
nerves,6 and its presence within sensory airway nerves
was reported recently.7 8
A potential role for tachykinins in asthma has been
suggested recently.9 1o From experiments in rodents it
was hypothesised that mechanical and chemical stim-
ulation of sensory airway nerve endings cause anti-
dromic release of substance P, neurokinin A and
calcitonin gene related peptide from axon collaterals,
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leading to smooth muscle contraction, mucus secre-
tion, vasodilatation, and protein extravasation (axon
reflex hypothesis). Substance P, however, when in-
haled has only a weak bronchoconstrictor effect. " In
animals and in isolated human airways, neurokinin A
is a more potent bronchoconstrictor than substance
p. '- 1 We decided to compare the effect of inhaling
substance P and neurokinin A on airway calibre of
normal and mildly asthmatic subjects.
Methods
PATIENTS
The study population consisted of six healthy, non-
smoking volunteers and six patients with a history of
mild asthma. The normal volunteers, two men and
four women, aged 24-35 years, had normal lung func-
tion (mean FEV1 115% of predicted, mean sGaw 1-92
(0-04) s'- kPa- '). The asthmatic patients, four men
and two women, aged 18-28 years, had only minor
symptoms during the weeks preceding the trial. Their
clinical characteristics are given in table 1. Five of the
six asthmatic subjects had positive skinprick test re-
sponses, five to house dust mite and two to grass pol-
len. Their FEV1 was greater than 70% predicted
(mean 80 (SEM 3)) and their PC20 (provocative con-
centration causing a 20% fall in FEV1) methacholine
less than 8 mg/ml. PC20 methacholine was determined
by measuring the FEV, decrease after inhalation of
doubling concentrations of methacholine, according
to the method described by Cockcroft etal.' 5
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Table I Clinical data on the six asthmatic subjects
PC20
Basal FEVI sGaw (methacholine, Skinprick test
Patient No Age (y) Sex Weight (kg) (% predicted) (s-I kPa-') mg/mi) response Treatment
1 18 M 65 74 0-79 2-60 D pt, gp S
2 22 F 57 84 2-04 2-20 Dpt, gp T + S
3 22 M 91 93 091 400 Dpt, gp S
4 27 F 56 78 1 86 5 50 Negative T + S + A
5 28 M 58 76 1-55 450 Dpt S
6 19 M 60 74 1-02 600 Dpt S
D pt, Dermatophagoides pteronyssinus; gp, grass pollen; S, inhaled sympathomimetic; A, inhaled anticholinergic; T, oral theophylline.
All subjects gave informed consent. The study de-
sign was approved by the ethical committee of the
University Hospital of Ghent.
MATERIALS AND SOLUTIONS
Substance P was obtained from UCB Bioproducts
(Brussels, Belgium), neurokinin A from Peninsula (St
Helens, England), and human serum albumin from
Behringwerke AG (Marburg, Germany).
The neuropeptides were dissolved in saline contain-
ing 1% human serum albumin. Saline containing 1%
human serum albumin served as a control solution
(pH 8-0, temperature 4°C, osmolality 320 mmol/kg).
The neuropeptides were diluted freshly each day and
kept on ice.
BRONCHIAL CHALLENGE
Subjects underwent a bronchial challenge with sub-
stance P, neurokinin A and a control solution in a
randomised order on three separate days. Solutions
were nebulised with a Wiesbadener-Doppel inhalator
(Wiesbadener Inhalatoren-Vertrieb, Wiesbaden, Ger-
many) with an airflow of 6 1 min'-. Increasing con-
centrations of substance P or neurokinin A were
inhaled(O1-9,5 x 10-9, 10-8,5 x 10-8, 10-7,5 x
10-7, and 10-6 mol/mI) at 15 minute intervals. Con-
trol solutions were administered in the same manner.
The nebulised solutions were inhaled during two
minutes of tidal breathing with the outlet of the nebu-
liser in the mouth and the nose closed by a clip. Under
these conditions 02 ml of the solution leaves the
nebuliser. The three challenges were performed at an
interval of at least one week. All medications taken by
the asthmatic patients (sympathomimetics and theo-
phylline) were stopped 24 hours before each chal-
lenge. The challenge tests were started at 2 pm.
LUNG FUNCTION MEASUREMENTS
The FEV1 was measured with a water sealed spi-
rometer (Expirograph, Godart) as the highest of three
consecutive measurements. Specific airway conduc-
tance (sGaw) was calculated from airway resistance
and thoracic gas volume measured with a constant
volume body plethysmograph (Jaeger, Wurzburg,
Germany). Measurements were made with the sub-
jects breathing quietly under BTPS conditions, in-
haling warmed, humidified air from a separate
rebreathing' bag to minimise temperature and hu-
midity artefacts. 6 Each value represents the mean of
eight consecutive measurements. sGaw was measured
before the start of the challenge and 5 and 15 minutes
after the start of inhalation for each concentration.
When sGaw had decreased by more than 35% it was
measured every 15 minutes until it had returned to
normal values.
STATISTICAL ANALYSIS
The results are expressed as the percentage change in
specific airway conductance (A % sGaw), and re-
ported as the means with standard errors in parenthe-
ses. The data from the two groups of subjects, the
three solutions, and the different concentrations were
compared by three way analysis of variance. Paired
data were compared by the Wilcoxon's matched pairs
signed rank test. A p value of < 0 05 was regarded as
significant.
Results
Inhalation of substance P and neurokinin A by the
healthy, non-smoking subjects did not cause a
significant change in sGaw (fig 1). Inhalation of sub-
40, r=.Inl
* Conbfol
'oSP
JNKA
I6-8
(moles/ml)
Fig I Percentage change (means with standard errors) in
sGaw in six normal subjectsfive minutes after inhalation of
increasing concentrations ofsubstance P (SP) and
neurokininA (NKA, A).
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Fig 2 Percentage change (means with
sGaw in six asthmatic subjects five minut
increasing concentrations ofsubstance P
neurokinin A (NKA).
stance P in concentrations up to 10
no significant change in sGaw int
jects. When the asthmatic subjects i
A, however, there was a fall in sG&,
The dose-response curve for the
with neurokinin A was significantly
curves obtained with substance P
solution (ANOVA, p <0.001). The
after inhalation of neurokinin A di]
from change in sGaw after substar
trol solution only at the concentra
mol/ml (p <0-05). At this conce:
sGaw of more than 35% had occu
six asthmatic subjects (mean fall 4
In the other patient (No 6) sGaw
24% after inhalation of the highesi
10-6 Mol/Ml.
Bronchoconstriction occurred
patients, with a >35% fall in sGa'
sGaw measured at 5 minutes wa
different from that measured at 15
sGaw had returned to baseline
minutes in three patients and withi
further patient, but it remained low at one hour
(A sGaw 62%) in one patient (No 5), whose initial
A sGaw was 86%. His bronchoconstriction was
rapidly alleviated by the administration of fenoterol.
All patients with a fall in sGaw reported chest tight-
ness. No change in heart rate or blood pressure and
no cough occurred. Bronchial responsiveness to
neuro-kinin A (PC35) did not correlate significantly
with bronchial reactivity to methacholine (PC20) in
the five patients with a reduction in sGaw greater
than 35% (log2 PC35 neurokinin A MOI/Ml V log2
PC20 mg/mi: r = -0.48).
Discussion
Inthis study we have shown that the inhalation of
nebulised neurokinin A caused bronchoconstriction
insubjects with mild asthma. Substance P in concen-
10-7 10-6 tations up to 10-6 mol/ml had no effect. No change
in specific airway conductance was seen after in-
standard errors) in halation of substance P or neurokinin A by non-
(es after inhalation of smoking healthy volunteers. Because of limitations in
'(SP) and the solubility of the tachykinins, concentrations
higher than 10-6 mol/ml were not given.
The absence of a bronchoconstrictor effect of sub-
6mol/ml caused stance P in our study is consistent with its rather weak
hfe asthmatic sub- effect on isolated human airway smooth muscle.'17 18
nhaled neurokinin Our finding that neurokinin A caused broncho-
aiw (fig 2, table 2). constriction in asthmatic subjects correlates well with
asthmatic subjects reports that it is a more potent bronchoconstrictor
different from the than substance P in animals'12 14 and the recent
and the control finding that it is between 100 and 1000 fold more
decrease in sGaw potent than substance P in contracting isolated
ffered significantly human airways.19 20 Neurokinin A caused broncho-
ice P and the con- constriction in the asthmatic patients, but had no
ttion of 5 x i0- 7 effect in the normal volunteers. This suggests that
,ntration a fall in bronchoconstriction was related to bronchial hyper-
irred in five of the responsiveness. In the five subjects with a greater than
~8% (SEM 12%)). 35% fall in sGaw no correlation was found between
decreased by only bronchial responsiveness to methacholine and neuro-
concentration of kinin A. These studies need to be extended to a larger
group of patients.
-apidly in the five Substance P and neurokinin A are members of a
w. The mean A % family of neuropeptides, the tachykinins.2 These are
.s not statistically structurally related peptides, containing 10-12 amino
minutes (table 2). acids, and sharing a common amidated C-terminal
values within 30 end (-Phe-X-Gly-Leu-Met-NH2). Until recently sub-
in 45 minutes in a stance P was the only tachykinin known to be present
Table 2 Mean percentage changes in sGaw (with standard errors in parentheses) after inhalation of neurokinin A in six-
asthmatic subjects
Concentration(MOt/mi): o95x 10-9 10-8 Sx O8 10-7 5 x10-7
5 min -8.2 (2-1) -5.0 (5-4) - I70 (6-0) -7171 (6-9) -21-8 (7-7) -48.0 (11-8)
15 min -7-5 (4-3) -6-8 (5-2) -6-3 (7-7) -14-3 (8-7) -12-2 (8-7) -42.8 (11-0)
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in mammalian nervous tissue. The other tachykinins
were extracted from amphibians (for example, kass-
inin, physalaemin) and molluscans (for example, el-
edoisin).2' On the basis of the different rank of order
of potencies displayed by various tachykinins when
tested with a variety of bioassays, the existence of
multiple substance P receptor subtypes has been pro-
posed.22 23 On the SP-P (P for physalaemin) subtype,
SP, physalaemin, eledoisin, and kassinin are more or
less equipotent, while kassinin and eledoisin are much
more active than substance P on the SP-E (E for el-
edoisin) receptor. Recently two new mammalian
tachykinins, neurokinin A (= substance K) and neu-
rokinin B (= neuromedin K) were discovered.5 24 Re-
cent data have shown that these two new tachykinins
are more potent on the SP-E than on the SP-P recep-
tor subtype.25 On the basis of animal studies'2-14
and findings from isolated human airways'9 20 a pre-
dominance of bronchial SP-E receptors has been pos-
tulated. Our results for human airways in vivo are
compatible with this view, as neurokinin A was
definitely more potent than substance P.
The mode of action of tachykinins in human air-
ways is not known. In addition to bronchial smooth
muscle contraction, substance P causes bronchial mi-
crovascular leakiness,26 airway mucus secretion,27
and histamine release from mast cells.28 Experiments
in rabbits and rats show that a considerable portion
of the bronchoconstrictor effect of tachykinins arises
from an interaction with cholinergic nerves, probably
through release of acetylcholine from cholinergic
nerve endings.'4 29 Studies on isolated human
bronchi suggested that substance P has a direct
smooth muscle contracting effect, as substance P in-
duced contraction is resistant to pretreatment with a
histamine and muscarinic receptor antagonist. '7 This
observation cannot, however, be extended to human
bronchi in vivo as nerve mediated responses are often
lost during in vitro studies.30 31 Inhalation of cap-
saicin, a neurotoxin that damages sensory nerve fibres
causing release of substance P, caused broncho-
constriction in man.32 The bronchoconstriction has a
rapid onset (under 20 seconds) and short duration
(under 60 seconds), and was found to be largely in-
hibited by the anticholinergic agent ipratropium bro-
mide. It is, however, questionable whether the
bronchoconstriction was due to release of substance P
or another tachykinin: capsaicin has been shown to
cause reflex bronchoconstriction in dogs33 and the
time course of capsaicin induced bronchoconstriction
was very different from the time course that we ob-
served after inhalation of neurokinin A by asthmatic
patients.
In conclusion, our study shows that tachykinins are
able to cause bronchoconstriction in asthmatic sub-
jects. As in animal and isolated human airways, neu-
Joos, Pauwels, van der Straeten
rokinin A is a more potent bronchoconstrictor than
substance P, suggesting a predominance of SP-E re-
ceptor sites in human airways. Axon reflexes could
therefore play a part in the pathogenesis of asthma.
The natural stimuli that cause tachykinin release from
sensory airway nerve endings are unknown at the
present. Further studies are necessary to define the
exact role and the mode of action of tachykinins in
human airways.
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